Want to see AU:IME full AI Analyst Report?
IME Stock Chart & Stats
AU$0.40
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.40
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.21 - AU$0.47
Previous CloseN/A
Volume202.98K
Average Volume (3M)9.67K
Market Cap
AU$19.31M
Enterprise ValueAU$17.42
Total Cash (Recent Filing)AU$1.99M
Total Debt (Recent Filing)AU$455.34K
Price to Earnings (P/E)101.4
Beta0.40
Next Earnings
Mar 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding54,395,714
10 Day Avg. Volume7,071
30 Day Avg. Volume9,667
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)1.29
Price to Sales (P/S)0.71
P/FCF Ratio83.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.37Price Target Upside-7.50% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$32.60M
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthRevenue growth accelerated materially in 2025 after a weak prior year, indicating improving commercial traction and broader business activity. If sustained, this expansion can support operating leverage, provide resources for reinvestment, and strengthen the company’s position in medical diagnostics and research.
Positive Operating And Free Cash FlowThe return to positive operating and free cash flow is an important improvement in internal funding capacity. Continued cash generation would reduce reliance on external capital, help finance operations and investment, and provide greater resilience while the company works toward profitability.
Conservative Balance SheetVery low and declining leverage gives ImExHS financial flexibility while earnings remain under pressure. A conservatively funded balance sheet limits interest and refinancing burdens, preserves capacity for strategic investment, and improves the company’s ability to withstand operating volatility.
Bears Say
Persistent Operating LossesOngoing net losses and a negative operating margin show that revenue growth has not yet translated into sustainable profitability. This weakens retained capital generation, limits the benefits of scale, and leaves the business dependent on execution improvements before earnings can become durable.
Sharp Gross Margin DeteriorationThe substantial gross margin contraction indicates that the economics of reported revenue have weakened even as growth improved. Lower gross profitability reduces the funds available to cover operating costs and makes future earnings more sensitive to pricing, delivery costs, and product mix.
Volatile Cash ConversionPositive cash flow in 2025 is not yet supported by a stable multi-year pattern. Volatile conversion can make funding needs harder to plan, weaken confidence in the durability of internal cash generation, and constrain investment if operating performance becomes less favorable.
ImExHS Limited News
IME FAQ
What was ImExHS Limited’s price range in the past 12 months?
ImExHS Limited lowest share price was AU$0.20 and its highest was AU$0.47 in the past 12 months.
What is ImExHS Limited’s market cap?
ImExHS Limited’s market cap is AU$19.31M.
When is ImExHS Limited’s upcoming earnings report date?
ImExHS Limited’s upcoming earnings report date is Mar 01, 2027 which is in 175 days.
How were ImExHS Limited’s earnings last quarter?
ImExHS Limited released its earnings results on Aug 27, 2026. The company reported AU$0.12 earnings per share for the quarter, beating the consensus estimate of -AU$0.05 by AU$0.17.
Is ImExHS Limited overvalued?
According to Wall Street analysts ImExHS Limited’s price is currently Overvalued.
Does ImExHS Limited pay dividends?
ImExHS Limited does not currently pay dividends.
What is ImExHS Limited’s EPS estimate?
ImExHS Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImExHS Limited have?
ImExHS Limited has 54,395,714 shares outstanding.
What happened to ImExHS Limited’s price movement after its last earnings report?
ImExHS Limited reported an EPS of AU$0.12 in its last earnings report, beating expectations of -AU$0.05. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ImExHS Limited?
Currently, no hedge funds are holding shares in AU:IME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImExHS Limited Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
ImExHS Limited
ImExHS Limited delivers cloud-powered medical imaging technologies to customers worldwide, including those in Australia. The firm specializes in the development and sale of modular imaging software systems, which encompass comprehensive information management platforms for disciplines such as radiology, cardiology, and pathology, alongside a robust picture archiving and communication system (PACS). Its principal software solutions include AQUILA for radiology, ALULA for pathology, and Antero for cardiology. Moreover, ImExHS offers STELLA.I, a suite of artificial intelligence tools hosted in the cloud, crafted to bolster diagnostic capabilities for medical professionals. The company further extends outsourced radiology and teleradiology services to hospitals and various other healthcare entities. Established in 2001, ImExHS Limited operates from its base in Mascot, Australia.
IME Stock 12 Month Forecast
Average Price Target
AU$0.37
▼(-7.50% Downside)
Technical Analysis
Oneview Healthcare Chess Depository Interests repr 1
―
Mach7 Technologies
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
PainChek Ltd
―